Tommi Suvitaival1, Isabel Bondia-Pons2, Laxman Yetukuri3, Päivi Pöhö4, John J Nolan2, Tuulia Hyötyläinen5, Johanna Kuusisto6, Matej Orešič7. 1. Steno Diabetes Center Copenhagen, DK-2820 Gentofte, Denmark. Electronic address: tommi.raimo.leo.suvitaival@regionh.dk. 2. Steno Diabetes Center Copenhagen, DK-2820 Gentofte, Denmark. 3. Institute for Molecular Medicine Finland, FI-00014, University of Helsinki, Helsinki, Finland; VTT Technical Research Centre of Finland, FI-02044 VTT, Espoo, Finland. 4. VTT Technical Research Centre of Finland, FI-02044 VTT, Espoo, Finland; Faculty of Pharmacy, FI-00014, University of Helsinki, Helsinki, Finland. 5. Steno Diabetes Center Copenhagen, DK-2820 Gentofte, Denmark; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland; Department of Chemistry, Örebro University, 702 81 Örebro, Sweden. 6. Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, FI-70211 Kuopio, Finland. 7. Steno Diabetes Center Copenhagen, DK-2820 Gentofte, Denmark; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland; School of Medical Sciences, Örebro University, 702 81 Örebro, Sweden.
Abstract
BACKGROUND: There is a need for early markers to track and predict the development of type 2 diabetes mellitus (T2DM) from the state of normal glucose tolerance through prediabetes. In this study we tested whether the plasma molecular lipidome has biomarker potential to predicting the onset of T2DM. METHODS: We applied global lipidomic profiling on plasma samples from well-phenotyped men (107 cases, 216 controls) participating in the longitudinal METSIM study at baseline and at five-year follow-up. To validate the lipid markers, an additional study with a representative sample of adult male population (n=631) was also conducted. A total of 277 plasma lipids were analyzed using the lipidomics platform based on ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry. Lipids with the highest predictive power for the development of T2DM were computationally selected, validated and compared to standard risk models without lipids. RESULTS: A persistent lipid signature with higher levels of triacylglycerols and diacyl-phospholipids as well as lower levels of alkylacyl phosphatidylcholines was observed in progressors to T2DM. Lysophosphatidylcholine acyl C18:2 (LysoPC(18:2)), phosphatidylcholines PC(32:1), PC(34:2e) and PC(36:1), and triacylglycerol TG(17:1/18:1/18:2) were selected to the full model that included metabolic risk factors and FINDRISC variables. When further adjusting for BMI and age, these lipids had respective odds ratios of 0.32, 2.4, 0.50, 2.2 and 0.31 (all p<0.05) for progression to T2DM. The independently-validated predictive power improved in all pairwise comparisons between the lipid model and the respective standard risk model without the lipids (integrated discrimination improvement IDI>0; p<0.05). Notably, the lipid models remained predictive of the development of T2DM in the fasting plasma glucose-matched subset of the validation study. CONCLUSION: This study indicates that a lipid signature characteristic of T2DM is present years before the diagnosis and improves prediction of progression to T2DM. Molecular lipid biomarkers were shown to have predictive power also in a high-risk group, where standard risk factors are not helpful at distinguishing progressors from non-progressors.
BACKGROUND: There is a need for early markers to track and predict the development of type 2 diabetes mellitus (T2DM) from the state of normal glucose tolerance through prediabetes. In this study we tested whether the plasma molecular lipidome has biomarker potential to predicting the onset of T2DM. METHODS: We applied global lipidomic profiling on plasma samples from well-phenotyped men (107 cases, 216 controls) participating in the longitudinal METSIM study at baseline and at five-year follow-up. To validate the lipid markers, an additional study with a representative sample of adult male population (n=631) was also conducted. A total of 277 plasma lipids were analyzed using the lipidomics platform based on ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry. Lipids with the highest predictive power for the development of T2DM were computationally selected, validated and compared to standard risk models without lipids. RESULTS: A persistent lipid signature with higher levels of triacylglycerols and diacyl-phospholipids as well as lower levels of alkylacyl phosphatidylcholines was observed in progressors to T2DM. Lysophosphatidylcholine acyl C18:2 (LysoPC(18:2)), phosphatidylcholines PC(32:1), PC(34:2e) and PC(36:1), and triacylglycerolTG(17:1/18:1/18:2) were selected to the full model that included metabolic risk factors and FINDRISC variables. When further adjusting for BMI and age, these lipids had respective odds ratios of 0.32, 2.4, 0.50, 2.2 and 0.31 (all p<0.05) for progression to T2DM. The independently-validated predictive power improved in all pairwise comparisons between the lipid model and the respective standard risk model without the lipids (integrated discrimination improvement IDI>0; p<0.05). Notably, the lipid models remained predictive of the development of T2DM in the fasting plasma glucose-matched subset of the validation study. CONCLUSION: This study indicates that a lipid signature characteristic of T2DM is present years before the diagnosis and improves prediction of progression to T2DM. Molecular lipid biomarkers were shown to have predictive power also in a high-risk group, where standard risk factors are not helpful at distinguishing progressors from non-progressors.
Authors: Santosh Lamichhane; Alex M Dickens; Partho Sen; Heikki Laurikainen; Faith Borgan; Jaana Suvisaari; Tuulia Hyötyläinen; Oliver Howes; Jarmo Hietala; Matej Orešič Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306
Authors: Marta Gonzalez-Freire; Ruin Moaddel; Kai Sun; Elisa Fabbri; Pingbo Zhang; Mohammed Khadeer; Norman Salem; Luigi Ferrucci; Richard D Semba Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-01 Impact factor: 6.053
Authors: Guanhong Miao; Ying Zhang; Zhiguang Huo; Wenjie Zeng; Jianhui Zhu; Jason G Umans; Gert Wohlgemuth; Diego Pedrosa; Brian DeFelice; Shelley A Cole; Amanda M Fretts; Elisa T Lee; Barbara V Howard; Oliver Fiehn; Jinying Zhao Journal: Diabetes Care Date: 2021-10-26 Impact factor: 19.112
Authors: Meghana D Gadgil; Alka M Kanaya; Caroline Sands; Matthew R Lewis; Namratha R Kandula; David M Herrington Journal: Diabet Med Date: 2020-12-25 Impact factor: 4.359